N@N

Cubist Pharmaceuticals Named One of Fortunea?s a100 Fastest-Growing Companiesa

^{Published on 2010-08-20 10:10:47 - Market Wire}
 

LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced it has been ranked 31^st on FORTUNEa™s 2010 a100 Fastest-Growing Companiesa list and the top pharmaceutical company. In the aProfit Growtha subgroup Cubist ranked 21^st. The magazine will be on the newsstands on August 23 and the full list is available today [ online ].

Michael W. Bonney, Cubist's president and CEO, said: aWe are honored to be included among some of the top performing companies in the world in the FORTUNE list of the a100 Fastest Growing Companies.a™ Our employees share the credit for making that possible. They are the ones who commit daily to our mission of defeating some of the most confounding drug-resistant bacteria known to man. Together we are making progress as is evident in our exciting and important pipeline programs.a

About the FORTUNE a100 Fastest-Growing Companiesa methodology

To qualify for the 100 Fastest-Growing Companies list, foreign or domestic companies had to meet the following criteria:

• Currently trading on a major U.S. stock exchange
• Quarterly reports filed with the SEC
• A minimum market capitalization of $250 million and a stock price of at least $5 as of June 30, 2010
• Continuously traded since June 30, 2007
• Revenue and net income of at least $50 million and $10 million, respectively, for the four quarters ended on or before April 30, 2010
• Posted an annualized growth in revenue and earnings per share of at least 15% annually over the three years ended on or before April 30, 2010

Companies that met the above criteria were ranked by revenue growth rate, EPS growth rate, and three-year annualized total return for the period ended June 30, 2010. The overall rank was based on the sum of the three ranks. Once the 100 companies were identified, they were then re-ranked within the 100, using the three equally weighted variables. If there was a tie, the company with the larger four-quarter revenue received the higher rank.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program, added with Cubista™s acquisition of Calixa Therapeutics Inc. in December 2009, focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea); and a Phase 1 program intended to address the unmet medical need for a treatment for serious infections caused by MDR Gram-negative pathogens. Cubist is also working on several pre-clinical programs being developed to address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.